Skip to main content
  • Register
  • Help
  • Contact us

Oncimmune Holdings plc (ONC) Ordinary 1p

Sell:230.00p Buy:239.00p 0 Change: 3.00p (1.29%)
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:230.00p
Buy:239.00p
Change: 3.00p (1.29%)
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:230.00p
Buy:239.00p
Change: 3.00p (1.29%)
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types. EarlyCDT-Lung is a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. EarlyCDT-Lung test is being used in the randomized trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland Early Childhood Longitudinal Study (ECLS) of over 12,000 high-risk smokers. It is also developing the EarlyCDT tests for other cancers, which include in particular the liver and ovarian cancers. It has sold over 145,000 tests in the United States and the United Kingdom.

Contact details

Address:
MediCity, D6 Building, 1 Thane Road
NOTTINGHAM
NG90 6BH
United Kingdom
Telephone:
+44 (0115) 7840500
Website:
https://oncimmune.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 15 February 2021 15/02/21
AGM 30 November 2020 30/11/20
Annual report 09 November 2020 09/11/20
Final results 30 October 2020 30/10/20
Trading Announcement 04 June 2020 04/06/20

General stock information

EPIC:
ONC
ISIN:
GB00BYQ94H38
Market cap:
£163.11 million
Shares in issue:
69.12 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Adam Hill
    Chief Executive Officer
  • Geoffrey Hamilton-Fairley
    Vice Chairman of the Board
  • Matthew Hall
    Group Chief Financial Officer
  • Greg Stanley
    President - Commercial Operations
  • Andrew Stewart
    General Counsel, Company Secretary
  • Dan Calvo
    Senior Advisor
  • James Jett
    Chief Medical Officer
  • Andrea Murray
    Chief Operational Scientist
  • Neal Navani
    Consultant Clinical Director
  • Laura Peek
    Principal Scientist & Assistant Lab Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.